Investors have pumped $60 million into Gilgamesh Pharma to test a handful of psychedelics and other experimental neuroscience medicines that the biotech hasn’t yet promised

MSD’s glut of pipeline-boosting deals in the build-up to a looming patent cliff is reported to be continuing with a $6bn bid to acquire Terns

Ocugen said it will take its gene therapy for a form of vision loss into a Phase 3 trial, after reporting mixed results on Tuesday

Given his former role as US national coordinator for health IT, you might expect that Farzad Mostashari would be an AI enthusiast. But his experience

Despite hitting just one of two efficacy endpoints in a pivotal trial, Karyopharm thinks it still has a path to approval for Xpovio in myelofibrosis.